Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Kardigan, Inc.
13D/A
Amendment 1
KARD · 485925101
|
8.8% |
10/1/2026
Event 9/29/2026
|
|||
| Perceptive Advisors LLC | 8.8% | ||||
| Joseph Edelman | 8.8% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 2.7% | ||||
| Perceptive Capital Solutions Holdings LP | 6.2% | ||||
|
Nurix Therapeutics, Inc.
13G
NRIX · 67080M103
|
5.3% |
9/23/2026
Event 9/16/2026
|
|||
| Perceptive Advisors LLC | 5.3% | ||||
| Joseph Edelman | 5.3% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.3% | ||||
|
Immatics N.V.
13D/A
Amendment 2
IMTX · N44445109
|
7.6% |
8/27/2026
Event 8/26/2026
|
|||
| Perceptive Advisors LLC | 7.6% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.6% | ||||
| Joseph Edelman | 7.6% | ||||
|
LeonaBio, Inc.
13D/A
Amendment 8
LONA · 04746L203
|
20.0% |
8/25/2026
Event 8/22/2026
|
|||
| Perceptive Advisors LLC | 20.0% | ||||
| Joseph Edelman | 20.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 16.5% | ||||
| Perceptive Xontogeny Venture Fund II, LP | 3.8% | ||||
|
Solid Biosciences Inc.
13D/A
Amendment 10
SLDB · 83422E204
|
11.2% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 11.2% | ||||
| Joseph Edelman | 11.2% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 11.2% | ||||
| Perceptive Xontogeny Venture Fund, LP | 0.1% | ||||
|
Spyre Therapeutics, Inc.
13G/A
Amendment 1
SYRE · 00773J202
|
4.9% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 4.9% | ||||
| Joseph Edelman | 4.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.9% | ||||
|
X4 Pharmaceuticals, Inc.
13G/A
Amendment 2
XFOR · 98420X202
|
8.1% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 8.1% | ||||
| Joseph Edelman | 8.1% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.1% | ||||
|
Tenax Therapeutics, Inc.
13G/A
Amendment 3
TENX · 88032L605
|
4.5% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 4.5% | ||||
| Joseph Edelman | 4.5% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.5% | ||||
|
Sutro Biopharma, Inc.
13G/A
Amendment 1
STRO · 869367201
|
7.9% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 7.9% | ||||
| Joseph Edelman | 7.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.9% | ||||
|
Sab Biotherapeutics, Inc.
13G/A
Amendment 2
SABS · 78397T202
|
7.3% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 7.3% | ||||
| Joseph Edelman | 7.3% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.3% | ||||
|
enVVeno Medical Corporation
13G/A
Amendment 8
NVNO · 29415J205
|
3.5% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 3.5% | ||||
| Joseph Edelman | 3.5% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 3.5% | ||||
|
Nautilus Biotechnology, Inc.
13D/A
Amendment 5
NAUT · 63909J108
|
9.1% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 9.1% | ||||
| Joseph Edelman | 9.1% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 9.1% | ||||
| C2 Life Sciences LLC | 0.1% | ||||
|
Invivyd, Inc.
13G/A
Amendment 1
IVVD · 00534A102
|
6.3% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 6.3% | ||||
| Joseph Edelman | 6.3% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 6.3% | ||||
|
Opus Genetics, Inc.
13G/A
Amendment 3
IRD · 67577R102
|
10.0% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Inhibrx Biosciences, Inc.
13G/A
Amendment 2
INBX · 45720N103
|
10.0% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Inhibikase Therapeutics, Inc.
13G/A
Amendment 3
IKT · 45719W205
|
6.9% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 6.9% | ||||
| Joseph Edelman | 6.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 6.9% | ||||
|
enGene Holdings Inc.
13G/A
Amendment 1
ENGN · 29286M105
|
10.0% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
BlossomHill Therapeutics, Inc.
13G
BLSM · 095130100
|
5.9% |
8/14/2026
Event 8/7/2026
|
|||
| Perceptive Advisors LLC | 5.9% | ||||
| Joseph Edelman | 5.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.9% | ||||
|
Alto Neuroscience, Inc.
13G/A
Amendment 2
ANRO · 02157Q109
|
10.0% |
8/14/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Relay Therapeutics, Inc.
13G/A
Amendment 1
RLAY · 75943R102
|
6.4% |
8/10/2026
Event 6/30/2026
|
|||
| Perceptive Advisors LLC | 6.4% | ||||
| Joseph Edelman | 6.4% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 6.4% | ||||
|
Kiora Pharmaceuticals, Inc.
13G
KPRX · 49721T507
|
10.0% |
8/10/2026
Event 4/6/2026
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Yarrow Bioscience, Inc.
13G
YARW · 92941V407
|
10.0% |
8/3/2026
Event 7/27/2026
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Freenome, Inc.
13G
FRNM · 35661P100
|
10.1% |
7/23/2026
Event 7/20/2026
|
|||
| Perceptive Advisors LLC | 10.1% | ||||
| Joseph Edelman | 10.1% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.1% | ||||
|
Research Alliance Corporation IV
13G
RACD · G75228109
|
7.7% |
7/20/2026
Event 7/13/2026
|
|||
| Perceptive Advisors LLC | 7.7% | ||||
| Joseph Edelman | 7.7% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.7% | ||||
|
Kardigan, Inc.
13D
KARD · 485925101
|
8.9% |
6/25/2026
Event 6/18/2026
|
|||
| Perceptive Advisors LLC | 8.9% | ||||
| Joseph Edelman | 8.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 2.7% | ||||
| Perceptive Capital Solutions Holdings LP | 6.2% | ||||
|
Research Alliance Corporation III
13G
RACC · G75226103
|
8.2% |
5/28/2026
Event 5/20/2026
|
|||
| Perceptive Advisors LLC | 8.2% | ||||
| Joseph Edelman | 8.2% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.2% | ||||
|
Palisade Bio, Inc.
13G/A
Amendment 2
PALI · 696389402
|
7.9% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 7.9% | ||||
| Joseph Edelman | 7.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.9% | ||||
|
Adagio Medical Holdings, Inc.
13G/A
Amendment 3
ADGM · 00534B100
|
55.4% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 55.4% | ||||
| Joseph Edelman | 55.4% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 54.7% | ||||
| C2 Life Sciences LLC | 0.9% | ||||
|
X4 Pharmaceuticals, Inc.
13G/A
Amendment 1
XFOR · 98420X202
|
7.3% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 7.3% | ||||
| Joseph Edelman | 7.3% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.3% | ||||
|
Inhibrx Biosciences, Inc.
13G/A
Amendment 1
INBX · 45720N103
|
10.0% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Biodesix, Inc.
13G/A
Amendment 1
BDSX · 09075X207
|
4.6% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 4.6% | ||||
| Joseph Edelman | 4.6% | ||||
| Perceptive Credit Advisors LLC | 4.6% | ||||
| Pcof Eq Aiv IV, LP | 0.5% | ||||
| Perceptive Credit Holdings IV, LP | 4.1% | ||||
|
Amylyx Pharmaceuticals, Inc.
13G/A
Amendment 4
AMLX · 03237H101
|
7.5% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 7.5% | ||||
| Joseph Edelman | 7.5% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.5% | ||||
|
Traws Pharma, Inc.
13G/A
Amendment 3
TRAW · 68232V884
|
6.1% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 6.1% | ||||
| Joseph Edelman | 6.1% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 6.1% | ||||
|
Rhythm Pharmaceuticals, Inc.
13G/A
Amendment 2
RYTM · 76243J105
|
5.1% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 5.1% | ||||
| Joseph Edelman | 5.1% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.1% | ||||
| Perceptive Capital Solutions Holdings LP | 1.1% | ||||
|
Inhibikase Therapeutics, Inc.
13G/A
Amendment 2
IKT · 45719W205
|
8.9% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 8.9% | ||||
| Joseph Edelman | 8.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.9% | ||||
|
Sab Biotherapeutics, Inc.
13G/A
Amendment 1
SABS · 78397T202
|
8.4% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 8.4% | ||||
| Joseph Edelman | 8.4% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.4% | ||||
|
enVVeno Medical Corporation
13G/A
Amendment 7
NVNO · 29415J205
|
10.0% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Aldeyra Therapeutics, Inc.
13G/A
Amendment 16
ALDX · 01438T106
|
0% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 0% | ||||
| Joseph Edelman | 0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | ||||
|
Tenax Therapeutics, Inc.
13G/A
Amendment 2
TENX · 88032L605
|
5.5% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 5.5% | ||||
| Joseph Edelman | 5.5% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.5% | ||||
|
CytomX Therapeutics, Inc.
13G/A
Amendment 1
CTMX · 23284F105
|
4.6% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 4.6% | ||||
| Joseph Edelman | 4.6% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.6% | ||||
|
Opus Genetics, Inc.
13G/A
Amendment 2
IRD · 67577R102
|
10.0% |
5/15/2026
Event 3/31/2026
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
LeonaBio, Inc.
13D/A
Amendment 7
LONA · 04746L203
|
20.0% |
5/7/2026
Event 5/5/2026
|
|||
| Perceptive Advisors LLC | 20.0% | ||||
| Joseph Edelman | 20.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 16.5% | ||||
| Perceptive Xontogeny Venture Fund II, LP | 3.7% | ||||
|
Avalyn Pharma Inc.
13G
AVLN · 05348Y105
|
6.0% |
5/7/2026
Event 4/30/2026
|
|||
| Perceptive Advisors LLC | 6.0% | ||||
| Joseph Edelman | 6.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 1.0% | ||||
| Perceptive Xontogeny Venture Fund II, L.P | 5.1% | ||||
|
Trinity Biotech plc
13D/A
Amendment 8
TRIB · 896438504
|
9.9% |
5/4/2026
Event 4/30/2026
|
|||
| Perceptive Advisors LLC | 9.9% | ||||
| Perceptive Credit Advisors LLC | 9.9% | ||||
| Joseph Edelman | 9.9% | ||||
| Perceptive Credit Holdings II, L.P. | 9.9% | ||||
| Perceptive Credit Holdings III, L.P. | 9.9% | ||||
|
MeiraGTx Holdings plc
13D/A
Amendment 8
MGTX · G59665102
|
12.6% |
4/24/2026
Event 4/17/2026
|
|||
| Perceptive Advisors LLC | 12.6% | ||||
| Joseph Edelman | 12.6% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 12.6% | ||||
|
Spyre Therapeutics, Inc.
13G
SYRE · 00773J202
|
5.0% |
4/22/2026
Event 4/15/2026
|
|||
| Perceptive Advisors LLC | 5.0% | ||||
| Joseph Edelman | 5.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.0% | ||||
|
Sutro Biopharma, Inc.
13G
STRO · 869367201
|
5.4% |
4/21/2026
Event 4/14/2026
|
|||
| Perceptive Advisors LLC | 5.4% | ||||
| Joseph Edelman | 5.4% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.4% | ||||
|
Zymeworks Inc.
13G
ZYME · 98985Y108
|
5.4% |
4/15/2026
Event 4/8/2026
|
|||
| Perceptive Advisors LLC | 5.4% | ||||
| Joseph Edelman | 5.4% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.4% | ||||
|
Kiora Pharmaceuticals, Inc.
13G
KPRX · 49721T507
|
10.0% |
4/13/2026
Event 4/6/2026
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Relay Therapeutics, Inc.
13G
RLAY · 75943R102
|
5.3% |
3/19/2026
Event 3/12/2026
|
|||
| Perceptive Advisors LLC | 5.3% | ||||
| Joseph Edelman | 5.3% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.3% | ||||
|
Edesa Biotech, Inc.
13G
EDSA · 27966L306
|
6.7% |
3/16/2026
Event 3/9/2026
|
|||
| Perceptive Advisors LLC | 6.7% | ||||
| Joseph Edelman | 6.7% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 6.7% | ||||
|
Solid Biosciences Inc.
13D/A
Amendment 9
SLDB · 83422E204
|
12.9% |
3/11/2026
Event 3/9/2026
|
|||
| Perceptive Advisors LLC | 12.9% | ||||
| Joseph Edelman | 12.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 12.8% | ||||
| Perceptive Xontogeny Venture Fund, LP | 0.1% | ||||
|
Celcuity Inc.
13G/A
Amendment 1
CELC · 15102K100
|
6.8% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 6.8% | ||||
| Joseph Edelman | 6.8% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 6.8% | ||||
|
Tenax Therapeutics, Inc.
13G/A
Amendment 1
TENX · 88032L605
|
9.1% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 9.1% | ||||
| Joseph Edelman | 9.1% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 9.1% | ||||
|
Opus Genetics, Inc.
13G/A
Amendment 1
IRD · 67577R102
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
enVVeno Medical Corporation
13G/A
Amendment 6
NVNO · 29415J106
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Praxis Precision Medicines, Inc.
13G/A
Amendment 1
PRAX · 74006W207
|
7.2% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 7.2% | ||||
| Joseph Edelman | 7.2% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.2% | ||||
|
Aldeyra Therapeutics, Inc.
13G/A
Amendment 15
ALDX · 01438T106
|
7.0% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 7.0% | ||||
| Joseph Edelman | 7.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.0% | ||||
|
Inhibikase Therapeutics, Inc.
13G/A
Amendment 1
IKT · 45719W205
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Palisade Bio, Inc.
13G/A
Amendment 1
PALI · 696389402
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Alto Neuroscience, Inc.
13G/A
Amendment 1
ANRO · 02157Q109
|
10.0% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Adagio Medical Holdings, Inc.
13G/A
Amendment 2
ADGM · 00534B100
|
57.5% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 57.5% | ||||
| Joseph Edelman | 57.5% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 56.8% | ||||
| C2 Life Sciences LLC | 0.8% | ||||
|
Travere Therapeutics, Inc.
13G/A
Amendment 1
TVTX · 89422G107
|
4.8% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 4.8% | ||||
| Joseph Edelman | 4.8% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.8% | ||||
|
Bright Minds Biosciences Inc.
13G/A
Amendment 2
DRUG · 10919W405
|
4.6% |
2/17/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 4.6% | ||||
| Joseph Edelman | 4.6% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.6% | ||||
|
Astria Therapeutics, Inc.
13D/A
Amendment 7
ATXS · 04635X102
|
0% |
2/9/2026
Event 1/26/2026
|
|||
| Perceptive Advisors LLC | 0% | ||||
| Joseph Edelman | 0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | ||||
| Perceptive Xontogeny Venture Fund, L.P. | 0% | ||||
|
Trinity Biotech plc
13D/A
Amendment 7
TRIB · 896438504
|
9.9% |
1/26/2026
Event 1/22/2026
|
|||
| Perceptive Advisors LLC | 9.9% | ||||
| Perceptive Credit Advisors LLC | 9.9% | ||||
| Joseph Edelman | 9.9% | ||||
| Perceptive Credit Holdings II, L.P. | 9.9% | ||||
| Perceptive Credit Holdings III, L.P. | 9.9% | ||||
|
Sab Biotherapeutics, Inc.
13G
SABS · 78397T202
|
7.3% |
1/22/2026
Event 1/14/2026
|
|||
| Perceptive Advisors LLC | 7.3% | ||||
| Joseph Edelman | 7.3% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.3% | ||||
|
LeonaBio, Inc.
13D/A
Amendment 6
LONA · 04746L203
|
20.0% |
1/16/2026
Event 1/16/2026
|
|||
| Perceptive Advisors LLC | 20.0% | ||||
| Joseph Edelman | 20.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 16.4% | ||||
| Perceptive Xontogeny Venture Fund II, LP | 3.5% | ||||
|
MeiraGTx Holdings plc
13D/A
Amendment 7
MGTX · G59665102
|
12.9% |
1/2/2026
Event 12/31/2025
|
|||
| Perceptive Advisors LLC | 12.9% | ||||
| Joseph Edelman | 12.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 12.9% | ||||
|
Athira Pharma, Inc.
13D/A
Amendment 5
LONA · 04746L203
|
20.1% |
12/23/2025
Event 12/23/2025
|
|||
| Perceptive Advisors LLC | 20.0% | ||||
| Joseph Edelman | 20.1% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 16.4% | ||||
| Perceptive Xontogeny Venture Fund II, LP | 3.5% | ||||
|
Trinity Biotech plc
13D/A
Amendment 6
TRIB · 896438504
|
9.9% |
12/23/2025
Event 12/22/2025
|
|||
| Perceptive Advisors LLC | 9.9% | ||||
| Perceptive Credit Advisors LLC | 9.9% | ||||
| Joseph Edelman | 9.9% | ||||
| Perceptive Credit Holdings II, L.P. | 9.9% | ||||
| Perceptive Credit Holdings III, L.P. | 9.9% | ||||
|
Tenax Therapeutics, Inc.
13G
TENX · 88032L605
|
7.0% |
12/23/2025
Event 12/18/2025
|
|||
| Perceptive Advisors LLC | 7.0% | ||||
| Joseph Edelman | 7.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.0% | ||||
|
Athira Pharma, Inc.
13D/A
Amendment 4
LONA · 04746L203
|
13.9% |
12/22/2025
Event 12/18/2025
|
|||
| Perceptive Advisors LLC | 13.7% | ||||
| Joseph Edelman | 13.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 13.7% | ||||
|
Lyra Therapeutics, Inc.
13D/A
Amendment 10
LYRA · 55234L204
|
0% |
11/25/2025
Event 11/21/2025
|
|||
| Perceptive Advisors LLC | 0% | ||||
| Joseph Edelman | 0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | ||||
| Perceptive LS (A), LLC | 0% | ||||
|
Invivyd, Inc.
13G
IVVD · 00534A102
|
7.9% |
11/25/2025
Event 11/18/2025
|
|||
| Perceptive Advisors LLC | 7.9% | ||||
| Joseph Edelman | 7.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.9% | ||||
|
Lyra Therapeutics, Inc.
13D/A
Amendment 9
LYRA · 55234L204
|
5.5% |
11/18/2025
Event 11/14/2025
|
|||
| Perceptive Advisors LLC | 5.5% | ||||
| Joseph Edelman | 5.5% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.0% | ||||
| Perceptive LS (A), LLC | 0.6% | ||||
|
enGene Holdings Inc.
13G
ENGN · 29286M105
|
10.0% |
11/18/2025
Event 11/11/2025
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Amylyx Pharmaceuticals, Inc.
13G/A
Amendment 3
AMLX · 03237H101
|
8.2% |
11/14/2025
Event 9/30/2025
|
|||
| Perceptive Advisors LLC | 8.2% | ||||
| Joseph Edelman | 8.2% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.2% | ||||
|
Artivion, Inc.
13G/A
Amendment 1
AORT · 228903100
|
4.3% |
11/14/2025
Event 9/30/2025
|
|||
| Perceptive Advisors LLC | 4.3% | ||||
| Joseph Edelman | 4.3% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.3% | ||||
|
Traws Pharma, Inc.
13G/A
Amendment 2
TRAW · 68232V884
|
10.0% |
11/14/2025
Event 9/30/2025
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
Orchestra BioMed Holdings, Inc.
13G/A
Amendment 3
OBIO · 68572M106
|
10.0% |
11/14/2025
Event 9/30/2025
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
KALA BIO, Inc.
13G/A
Amendment 1
KALA · 483119202
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| Perceptive Advisors LLC | 0% | ||||
| Joseph Edelman | 0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | ||||
|
Inventiva S.A.
13G/A
Amendment 1
IVA · 46124U107
|
4.99% |
11/14/2025
Event 9/30/2025
|
|||
| Perceptive Advisors LLC | 4.99% | ||||
| Joseph Edelman | 4.99% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.99% | ||||
|
Verona Pharma plc
13G/A
Amendment 3
VRNA · 925050106
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| Perceptive Advisors LLC | 0% | ||||
| Joseph Edelman | 0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | ||||
|
Aldeyra Therapeutics, Inc.
13G/A
Amendment 14
ALDX · 01438T106
|
8.7% |
11/14/2025
Event 9/30/2025
|
|||
| Perceptive Advisors LLC | 8.7% | ||||
| Joseph Edelman | 8.7% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.7% | ||||
|
Lyra Therapeutics, Inc.
13D/A
Amendment 8
LYRA · 55234L204
|
7.8% |
11/13/2025
Event 11/11/2025
|
|||
| Perceptive Advisors LLC | 7.8% | ||||
| Joseph Edelman | 7.8% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.0% | ||||
| Perceptive LS (A), LLC | 0.8% | ||||
|
Lyra Therapeutics, Inc.
13D/A
Amendment 7
LYRA · 55234L204
|
11.2% |
11/10/2025
Event 11/6/2025
|
|||
| Perceptive Advisors LLC | 11.2% | ||||
| Joseph Edelman | 11.2% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.1% | ||||
| Perceptive LS (A), LLC | 1.1% | ||||
|
X4 Pharmaceuticals, Inc.
13G
XFOR · 98420X202
|
7.6% |
11/3/2025
Event 10/27/2025
|
|||
| Perceptive Advisors LLC | 7.6% | ||||
| Joseph Edelman | 7.6% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.6% | ||||
|
Trinity Biotech plc
13D/A
Amendment 5
TRIB · 896438504
|
22.5% |
10/24/2025
Event 10/23/2025
|
|||
| Perceptive Advisors LLC | 22.5% | ||||
| Perceptive Credit Advisors LLC | 22.5% | ||||
| Joseph Edelman | 22.5% | ||||
| Perceptive Credit Holdings II, L.P. | 10.2% | ||||
| Perceptive Credit Holdings III, L.P. | 12.3% | ||||
|
Astria Therapeutics, Inc.
13D/A
Amendment 6
ATXS · 04635X102
|
11.5% |
10/16/2025
Event 10/14/2025
|
|||
| Perceptive Advisors LLC | 11.5% | ||||
| Joseph Edelman | 11.5% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 8.6% | ||||
| Perceptive Xontogeny Venture Fund, L.P. | 2.9% | ||||
|
Travere Therapeutics, Inc.
13G
TVTX · 89422G107
|
5.5% |
10/14/2025
Event 10/6/2025
|
|||
| Perceptive Advisors LLC | 5.5% | ||||
| Joseph Edelman | 5.5% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.5% | ||||
|
Alto Neuroscience, Inc.
13G
ANRO · 02157Q109
|
7.3% |
10/10/2025
Event 10/3/2025
|
|||
| Perceptive Advisors LLC | 7.3% | ||||
| Joseph Edelman | 7.3% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.3% | ||||
|
Palisade Bio, Inc.
13G
PALI · 696389402
|
10.0% |
10/9/2025
Event 10/2/2025
|
|||
| Perceptive Advisors LLC | 10.0% | ||||
| Joseph Edelman | 10.0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 10.0% | ||||
|
KALA BIO, Inc.
13G
KALA · 483119202
|
7.7% |
9/11/2025
Event 9/4/2025
|
|||
| Perceptive Advisors LLC | 7.7% | ||||
| Joseph Edelman | 7.7% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 7.7% | ||||
|
CytomX Therapeutics, Inc.
13G
CTMX · 23284F105
|
5.9% |
8/21/2025
Event 8/14/2025
|
|||
| Perceptive Advisors LLC | 5.9% | ||||
| Joseph Edelman | 5.9% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 5.9% | ||||
|
Lyra Therapeutics, Inc.
13D/A
Amendment 6
LYRA · 55234L105
|
15.6% |
8/14/2025
Event 8/12/2025
|
|||
| Perceptive Advisors LLC | 15.6% | ||||
| Joseph Edelman | 15.6% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 14.0% | ||||
| Perceptive LS (A), LLC | 1.6% | ||||
|
OnKure Therapeutics, Inc.
13G/A
Amendment 1
OKUR · 68277Q105
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| Perceptive Advisors LLC | |||||
| Joseph Edelman | 0% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 0% | ||||
|
Contineum Therapeutics, Inc.
13G/A
Amendment 3
CTNM · 21217B100
|
3.2% |
8/14/2025
Event 6/30/2025
|
|||
| Perceptive Advisors LLC | 3.2% | ||||
| Joseph Edelman | 3.2% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 3.2% | ||||
|
Amicus Therapeutics, Inc.
13G/A
Amendment 5
FOLD · 03152W109
|
2.4% |
8/14/2025
Event 6/30/2025
|
|||
| Perceptive Advisors LLC | 2.4% | ||||
| Joseph Edelman | 2.4% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 2.4% | ||||
|
Edgewise Therapeutics, Inc.
13G/A
Amendment 2
EWTX · 28036F105
|
4.4% |
8/14/2025
Event 6/30/2025
|
|||
| Perceptive Advisors LLC | 4.4% | ||||
| Joseph Edelman | 4.4% | ||||
| Perceptive Life Sciences Master Fund, Ltd. | 4.4% | ||||